- Home
- SNTI vs TENX Comparison
SNTI vs TENX Comparison
Compare SNTI & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNTI
- TENX
- Stock Information
- Founded
- SNTI 2016
- TENX 1967
- Country
- SNTI United States
- TENX United States
- Employees
- SNTI 48
- TENX N/A
- Industry
- SNTI Biotechnology: Pharmaceutical Preparations
- TENX Biotechnology: Pharmaceutical Preparations
- Sector
- SNTI Health Care
- TENX Health Care
- Exchange
- SNTI Nasdaq
- TENX Nasdaq
- Market Cap
- SNTI 18.2M
- TENX 19.5M
- IPO Year
- SNTI N/A
- TENX N/A
- Fundamental
- Price
- SNTI $3.97
- TENX $5.61
- Analyst Decision
- SNTI Strong Buy
- TENX Strong Buy
- Analyst Count
- SNTI 1
- TENX 4
- Target Price
- SNTI $12.00
- TENX $20.67
- AVG Volume (30 Days)
- SNTI 7.2M
- TENX 67.4K
- Earning Date
- SNTI 11-14-2024
- TENX 11-13-2024
- Dividend Yield
- SNTI N/A
- TENX N/A
- EPS Growth
- SNTI N/A
- TENX N/A
- EPS
- SNTI N/A
- TENX N/A
- Revenue
- SNTI N/A
- TENX N/A
- Revenue This Year
- SNTI $254.47
- TENX N/A
- Revenue Next Year
- SNTI $169.66
- TENX N/A
- P/E Ratio
- SNTI N/A
- TENX N/A
- Revenue Growth
- SNTI N/A
- TENX N/A
- 52 Week Low
- SNTI $1.52
- TENX $2.77
- 52 Week High
- SNTI $16.94
- TENX $27.36
- Technical
- Relative Strength Index (RSI)
- SNTI 47.37
- TENX 54.30
- Support Level
- SNTI $3.60
- TENX $5.70
- Resistance Level
- SNTI $5.96
- TENX $6.01
- Average True Range (ATR)
- SNTI 1.02
- TENX 0.47
- MACD
- SNTI -0.29
- TENX -0.08
- Stochastic Oscillator
- SNTI 5.74
- TENX 12.15
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with their gene circuit platform technologies to fight challenging diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.